Special Issue

Pyrazole and Its Derivatives: Drug Design, Synthesis, and Biological Evaluation

Message from the Guest Editors

The pyrazole nucleus represents a pivotal building block in a broad range of areas including organic and medicinal chemistry, food industries, and agricultural systems. Furthermore, pyrazole-based compounds have been widely described as pharmaceutically active derivatives endowed with a plethora of biological properties such as anti-inflammatory, anticonvulsant, anticancer, antidepressant, antibacterial, antifungal, analgesic, and antiviral. The pharmacological attractiveness of the pyrazole nucleus is probably due to its particular chemical behavior. In fact, the unshared electrons of the two nitrogen atoms (namely, "pyrrolelike" and "pyridine-like" nitrogens) differently contribute to the resonance of this heterocycle, being uniquely the lone pair of the "pyrrole-like" nitrogen conjugated with the aromatic system. These characteristics allow for the reaction between the nucleus and both acids and bases, making it a perfect building block. Based on this evidence, the current Special Issue aims to enrich the scientific knowledge around the pyrazole scaffold and further support the pharmaceutical interest on pyrazolebased derivatives.

Guest Editors

Dr. Matteo Lusardi

Department of Pharmacy, Università degli Studi di Genova, Viale Benedetto XV 3, I-16132 Genova, Italy

Dr. Marco Ponassi

IRCCS Ospedale Policlinico San Martino, Proteomics and Mass Spectrometry Unit, L.go. R. Benzi, 10, 16132 Genova, Italy

Deadline for manuscript submissions

28 February 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/247739

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

